Oncologist Jakub Svoboda, MD, offers an overview of recent advances in the treatment of Hodgkin Lymphoma, including new biological and targeted agents, optimal combinations and the evolving concept of limiting therapy to better manage acute and long-term toxicities while achieving cure.
Related Links
- Enrolling Clinical Trials: Adoptive Immunotherapy for Chemotherapy Resistant or Refractory CD-19+ Leukemia and Lymphoma
- Case Study: A 65-year-old male with CLL refractory to purine analogs treated with CTL-019 after relapse demonstrated by extensive marrow infiltration and diffuse adenopathy
- Dr Svoboda’s Profile
Published
August 14, 2014
Created by
BROADCASTMED